Development of a novel drug for neurodegenerative disease and migraine
- Detailed Technology Description
- Title: Development of a Novel Drug for Neurodegenerative Disease and Migraine Invention: The invention is the development of pituitary adenylate cyclase activating peptide (PACAP) agonists for neuroprotection and antagonists for migraine. Background: PACAP is known as a neuronal survival factor, regulating the development, maintenance, function, and plasticity of neurons through activating PAC1, VPAC1, and VPAC2 receptors. Glycosylated PACAP analogues have been found to penetrate the blood-brain barrier (BBB) at a high rate. In addition, VPAC1/2 receptors are involved in vasodilation and may contribute to migraine attacks. It is possible to treat these migraine attacks by using PACAP antagonists. Applications: A novel drug compound for the treatment of Parkinson’s disease and other neurodegenerative diseasesMay provide a novel technique to improve BBB permeability Advantages: Improves BBB permeability Possible treatment of migrainesAccessing the central nervous system (CNS) through the BBB may provide better treatment options Licensing Manager:Laura SilvaLauraS@tla.arizona.edu(520) 626-1557
- *Abstract
-
None
- *Principal Investigator
-
Name: Robin Polt, Professor
Department: Chemistry & Biochemistry
Name: Evan Jones, Graduate Assistant
Department: Chemistry & Biochemistry
Name: Bobbi Anglin, Instructor
Department: CBC
Name: Michael Heien, Associate Professor
Department: Chemistry & Biochemistry
Name: John Streicher
Department:
- Country/Region
- USA
For more information, please click Here
